Carboplatin Plus Pemetrexed as First-line Treatment of Patients With Malignant Pleural Mesothelioma: A Phase II Study
Tóm tắt
Từ khóa
Tài liệu tham khảo
Vogelzang, 2003, Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma, J Clin Oncol, 21, 2636, 10.1200/JCO.2003.11.136
Kalmadi, 2008, Gemcitabine and cisplatin in unresectable malignant mesothelioma of the pleura: a phase II study of the Southwest Oncology Group (SWOG 9810), Lung Cancer, 60, 259, 10.1016/j.lungcan.2007.09.018
Maziak, 2005, Surgical management of malignant pleural mesothelioma: a systematic review and evidence summary, Lung Cancer, 48, 157, 10.1016/j.lungcan.2004.11.003
Tomek, 2004, Chemotherapy for malignant pleural mesothelioma: past results and recent developments, Lung Cancer, 45, 103, 10.1016/j.lungcan.2004.04.020
Ellis, 2006, The use of chemotherapy in patients with advanced malignant pleural mesothelioma: a systematic review and practice guideline, J Thorac Oncol, 1, 591, 10.1097/01243894-200607000-00017
British Thoracic Society Standards of Care Committee, 2007, BTS statement on malignant mesothelioma in the UK, 2007, Thorax, 62, ii1, 10.1136/thx.2007.087619
Berghmans, 2002, Activity of chemotherapy and immunotherapy on malignant mesothelioma: A systematic review of the literature with meta-analysis, Lung Cancer, 38, 111, 10.1016/S0169-5002(02)00180-0
Favaretto, 2005, Overview on ongoing or planned clinical trials in Europe, Lung Cancer, 49, 117, 10.1016/j.lungcan.2005.03.022
Scagliotti, 2003, Phase II study of pemetrexed with and without folic acid and vitamin B12 as front-line therapy in malignant pleural mesothelioma, J Clin Oncol, 21, 1556, 10.1200/JCO.2003.06.122
Thödtmann, 1999, Clinical and pharmacokinetic phase I study of multitargeted antifolate (LY231514) in combination with cisplatin, J Clin Oncol, 17, 3009, 10.1200/JCO.1999.17.10.3009
Calvert, 2000, Alimta in combination with carboplatin demonstrates clinical activity against malignant mesothelioma in a phase I trial, Lung Cancer, 29, 73
Obasaju, 2007, Single-arm, open label study of pemetrexed plus cisplatin in chemotherapy naïve patients with malignant pleural mesothelioma: outcomes of an expanded access program, Lung Cancer, 55, 187, 10.1016/j.lungcan.2006.09.023
Santoro, 2008, Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemonaïve patients with malignant pleural mesothelioma: results of the International Expanded Access Program, J Thorac Oncol, 3, 756, 10.1097/JTO.0b013e31817c73d6
Hazarika, 2004, FDA drug approval summaries: pemetrexed (Alimta), The Oncologist, 9, 482, 10.1634/theoncologist.9-5-482
Lee, 2009, Outcomes with first-line platinum-based combination chemotherapy for malignant pleural mesothelioma: a review of practice in British Columbia, Lung Cancer, 64, 308, 10.1016/j.lungcan.2008.09.008
Ceresoli, 2006, Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma, J Clin Oncol, 24, 1443, 10.1200/JCO.2005.04.3190
Castagneto, 2008, Phase II study of pemetrexed in combination with carboplatin in patients with malignant pleural mesothelioma (MPM), Ann Oncol, 19, 370, 10.1093/annonc/mdm501
Li, 2009, Carboplatin and pemetrexed in the management of malignant pleural mesothelioma: A realistic treatment option?, Lung Cancer, 64, 207, 10.1016/j.lungcan.2008.08.016
Byrne, 1999, Cisplatin and gemcitabine treatment for malignant mesothelioma: a phase II study, J Clin Oncol, 17, 25, 10.1200/JCO.1999.17.1.25
Nowak, 2002, A multicenter phase II study of cisplatin and gemcitabine for malignant mesothelioma, Br J Cancer, 87, 491, 10.1038/sj.bjc.6600505
Pinto, 2006, Sequential chemotherapy with cisplatin/gemcitabine (CG) followed by mitoxantrone/methotrexate/mitomycin (MMM) in patients with malignant mesothelioma. A multicenter Italian Phase II Study (SITMP1), Lung Cancer, 52, 199, 10.1016/j.lungcan.2006.01.002
Ardizzoni, 1991, Activity of doxorubicin and cisplatin combination chemotherapy in patients with diffuse malignant pleural mesothelioma: An Italian Lung Cancer Task Force (FONICAP) Phase II study, Cancer, 67, 2984, 10.1002/1097-0142(19910615)67:12<2984::AID-CNCR2820671208>3.0.CO;2-Q
Chahinian, 1993, Randomized phase II trial of cisplatin with mitomycin or doxorubicin for malignant mesothelioma by the Cancer and Leukemia Group B, J Clin Oncol, 11, 1559, 10.1200/JCO.1993.11.8.1559
Fizazi, 2003, Combination of raltitrexed and oxaliplatin is an active regimen in malignant mesothelioma: results of a phase II study, J Clin Oncol, 21, 349, 10.1200/JCO.2003.05.123
Schutte, 2003, A multicenter phase II study of gemcitabine and oxaliplatin for malignant pleural mesothelioma, Clin Lung Cancer, 4, 294, 10.3816/CLC.2003.n.009
Fennell, 2005, Phase II trial of vinorelbine and oxaliplatin as first-line therapy in malignant pleural mesothelioma, Lung Cancer, 47, 277, 10.1016/j.lungcan.2004.08.005
Karrison, 2007, Final analysis of a multi-center, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin (GC) plus bevacizumab (B) or placebo (P) in patients (pts) with malignant mesothelioma (MM), J Clin Oncol, 25, 391s
Krug, 2007, A multicenter U.S. trial of neoadjuvant pemetrexed plus cisplatin (PC) followed by extrapleural pneumonectomy (EPP) and hemithoracic radiation (RT) for stage I-III malignant pleural mesothelioma (MPM), J Clin Oncol, 25, 399s
International Mesothelioma Interest Group, 1995, A proposed new international TNM staging system for malignant pleural mesothelioma, Chest, 108, 1122, 10.1378/chest.108.4.1122
Cockroft, 1976, Prediction of creatinine clearance from serum creatinine, Nephron, 16, 31, 10.1159/000180580
Therasse, 2000, New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of cancer, National Cancer Institute of the United States, National Cancer Institute of Canada, J Natl Cancer Inst, 92, 205, 10.1093/jnci/92.3.205
Hazarika, 2005, Pemetrexed in malignant pleural mesothelioma, Clin Cancer Res, 11, 982, 10.1158/1078-0432.982.11.3
Oxnard, 2005, Development of response criteria for mesothelioma based on mathematical model, J Clin Oncol, 23, 664s
Fennell, 2005, Response of malignant pleural mesothelioma to chemotherapy does not confer a survival advantage, Lung Cancer, 49, S220